Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Lung Cancer

  Free Subscription

Articles published in Br J Cancer

Retrieve available abstracts of 94 articles:
HTML format

Single Articles

    June 2022
  1. LYTHGOE MP, Prasad V
    Repositioning canakinumab for non-small cell lung cancer-important lessons for drug repurposing in oncology.
    Br J Cancer. 2022 Jun 23. pii: 10.1038/s41416-022-01893.
    PubMed     Abstract available

    May 2022
  2. MIN HY, Lee HJ, Suh YA, Pei H, et al
    Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase.
    Br J Cancer. 2022 May 21. pii: 10.1038/s41416-022-01843.
    PubMed     Abstract available

  3. GREENE G, Griffiths R, Han J, Akbari A, et al
    Impact of the SARS-CoV-2 pandemic on female breast, colorectal and non-small cell lung cancer incidence, stage and healthcare pathway to diagnosis during 2020 in Wales, UK, using a national cancer clinical record system.
    Br J Cancer. 2022 May 2. pii: 10.1038/s41416-022-01830.
    PubMed     Abstract available

  4. EDWARDS CJ, Sette A, Cox C, Di Fiore B, et al
    The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity.
    Br J Cancer. 2022;126:1168-1177.
    PubMed     Abstract available

    April 2022
  5. ZHANG B, Stewart CA, Wang Q, Cardnell RJ, et al
    Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer.
    Br J Cancer. 2022 Apr 19. pii: 10.1038/s41416-022-01811.
    PubMed     Abstract available

  6. MURCIANO-GOROFF YR, Pak T, Mondaca S, Flynn JR, et al
    Immune biomarkers and response to checkpoint inhibition of BRAF(V600) and BRAF non-V600 altered lung cancers.
    Br J Cancer. 2022;126:889-898.
    PubMed     Abstract available

    March 2022
  7. BONANNO L, Dal Maso A, Pavan A, Zulato E, et al
    Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?
    Br J Cancer. 2022 Mar 9. pii: 10.1038/s41416-022-01777.
    PubMed     Abstract available

    February 2022
  8. WEI S, Liu W, Xu M, Qin H, et al
    Cathepsin F and Fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer.
    Br J Cancer. 2022 Feb 25. pii: 10.1038/s41416-022-01744.
    PubMed     Abstract available

  9. ZHANG P, Chen PL, Li ZH, Zhang A, et al
    Association of smoking and polygenic risk with the incidence of lung cancer: a prospective cohort study.
    Br J Cancer. 2022 Feb 22. pii: 10.1038/s41416-022-01736.
    PubMed     Abstract available

  10. PATEL AJ, Tan TM, Richter AG, Naidu B, et al
    A highly predictive autoantibody-based biomarker panel for prognosis in early-stage NSCLC with potential therapeutic implications.
    Br J Cancer. 2022;126:238-246.
    PubMed     Abstract available

    November 2021
  11. TAMMINGA M, Andree KC, van den Bos H, Hiltermann TJN, et al
    Leukapheresis increases circulating tumour cell yield in non-small cell lung cancer, counts related to tumour response and survival.
    Br J Cancer. 2021 Nov 30. pii: 10.1038/s41416-021-01634.
    PubMed     Abstract available

  12. CAMINA N, Penning TM
    Genetic and epigenetic regulation of the NRF2-KEAP1 pathway in human lung cancer.
    Br J Cancer. 2021 Nov 29. pii: 10.1038/s41416-021-01642.
    PubMed     Abstract available

  13. ALIAGAS E, Alay A, Martinez-Iniesta M, Hernandez-Madrigal M, et al
    Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma.
    Br J Cancer. 2021;125:1365-1376.
    PubMed     Abstract available

  14. GARINET S, Didelot A, Denize T, Perrier A, et al
    Clinical assessment of the miR-34, miR-200, ZEB1 and SNAIL EMT regulation hub underlines the differential prognostic value of EMT miRs to drive mesenchymal transition and prognosis in resected NSCLC.
    Br J Cancer. 2021;125:1544-1551.
    PubMed     Abstract available

    October 2021
  15. BALL S, Hyde C, Hamilton W, Bright CJ, et al
    An evaluation of a national mass media campaign to raise public awareness of possible lung cancer symptoms in England in 2016 and 2017.
    Br J Cancer. 2021 Oct 30. pii: 10.1038/s41416-021-01573.
    PubMed     Abstract available

  16. HOPKINS AM, Kichenadasse G, McKinnon RA, Abuhelwa AY, et al
    Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150.
    Br J Cancer. 2021 Oct 28. pii: 10.1038/s41416-021-01606.
    PubMed     Abstract available

  17. MARTINEZ-MARTI A, Felip E, Mancuso FM, Caratu G, et al
    Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer.
    Br J Cancer. 2021 Oct 1. pii: 10.1038/s41416-021-01558.
    PubMed     Abstract available

    September 2021
  18. LINDSAY CR, Shaw EC, Moore DA, Rassl D, et al
    Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists.
    Br J Cancer. 2021 Sep 6. pii: 10.1038/s41416-021-01407.
    PubMed     Abstract available

    August 2021
  19. ROSELL R, Cardona AF, Arrieta O, Aguilar A, et al
    Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities.
    Br J Cancer. 2021 Aug 9. pii: 10.1038/s41416-021-01519.
    PubMed     Abstract available

  20. NI Y, Peng J, Yang X, Wei Z, et al
    Multicentre study of microwave ablation for pulmonary oligorecurrence after radical resection of non-small-cell lung cancer.
    Br J Cancer. 2021;125:672-678.
    PubMed     Abstract available

  21. LAPIDOT M, Case AE, Weisberg EL, Meng C, et al
    Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
    Br J Cancer. 2021;125:582-592.
    PubMed     Abstract available

    Molecularly profiled trials: toward a framework of actions for the "nil actionables".
    Br J Cancer. 2021;125:473-478.
    PubMed     Abstract available

    July 2021
  23. SUI Y, Hu W, Zhang W, Li D, et al
    Insights into homeobox B9: a propeller for metastasis in dormant prostate cancer progenitor cells.
    Br J Cancer. 2021 Jul 10. pii: 10.1038/s41416-021-01482.
    PubMed     Abstract available

  24. MU W, Katsoulakis E, Whelan CJ, Gage KL, et al
    Radiomics predicts risk of cachexia in advanced NSCLC patients treated with immune checkpoint inhibitors.
    Br J Cancer. 2021;125:229-239.
    PubMed     Abstract available

  25. JOSEPH R, Soundararajan R, Vasaikar S, Yang F, et al
    CD8(+) T cells inhibit metastasis and CXCL4 regulates its function.
    Br J Cancer. 2021;125:176-189.
    PubMed     Abstract available

  26. GUO L, Kaumaya PTP
    First prototype checkpoint inhibitor B-cell epitope vaccine (PD1-Vaxx) en route to human Phase 1 clinical trial in Australia and USA: exploiting future novel synergistic vaccine combinations.
    Br J Cancer. 2021;125:152-154.
    PubMed     Abstract available

    June 2021
  27. CHEN F, Han Y, Kang Y
    Bone marrow niches in the regulation of bone metastasis.
    Br J Cancer. 2021;124:1912-1920.
    PubMed     Abstract available

    May 2021
  28. GELSOMINO F, Tiseo M, Barbieri F, Riccardi F, et al
    Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
    Br J Cancer. 2021 May 19. pii: 10.1038/s41416-021-01439.

  29. CHENG Y, Wang Q, Li K, Shi J, et al
    Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study.
    Br J Cancer. 2021 May 18. pii: 10.1038/s41416-021-01356.
    PubMed     Abstract available

  30. ROBBINS HA, Alcala K, Swerdlow AJ, Schoemaker MJ, et al
    Correction: Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom.
    Br J Cancer. 2021 May 17. pii: 10.1038/s41416-021-01436.

  31. ROUND T, L'Esperance V, Bayly J, Brain K, et al
    COVID-19 and the multidisciplinary care of patients with lung cancer: an evidence-based review and commentary.
    Br J Cancer. 2021 May 10. pii: 10.1038/s41416-021-01361.
    PubMed     Abstract available

  32. LIN JJ, Gainor JF
    An early look at selective RET inhibitor resistance: new challenges and opportunities.
    Br J Cancer. 2021;124:1757-1758.
    PubMed     Abstract available

  33. LARIJANI B, Miles J, Ward SG, Parker PJ, et al
    Quantification of biomarker functionality predicts patient outcomes.
    Br J Cancer. 2021;124:1618-1620.
    PubMed     Abstract available

    April 2021
  34. ROBBINS HA, Alcala K, Swerdlow AJ, Schoemaker MJ, et al
    Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom.
    Br J Cancer. 2021 Apr 12. pii: 10.1038/s41416-021-01278.
    PubMed     Abstract available

    March 2021
  35. JIANG Y, Martin J, Alkadhimi M, Shigemori K, et al
    Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model.
    Br J Cancer. 2021 Mar 19. pii: 10.1038/s41416-021-01296.
    PubMed     Abstract available

  36. RAKAEE M, Kilvaer TK, Jamaly S, Berg T, et al
    Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01307.
    PubMed     Abstract available

  37. YANG H, Hall SRR, Sun B, Yao F, et al
    Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy".
    Br J Cancer. 2021;124:1177-1178.

  38. WHITE MG, Eng OS
    Response to Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy".
    Br J Cancer. 2021;124:1179-1180.

  39. JIA L, Ge X, Du C, Chen L, et al
    EEF1A2 interacts with HSP90AB1 to promote lung adenocarcinoma metastasis via enhancing TGF-beta/SMAD signalling.
    Br J Cancer. 2021;124:1301-1311.
    PubMed     Abstract available

  40. SHIRASAWA M, Yoshida T, Horinouchi H, Kitano S, et al
    Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment.
    Br J Cancer. 2021;124:925-932.
    PubMed     Abstract available

    February 2021
  41. ROSENTHAL R, Swanton C, McGranahan N
    Understanding the impact of immune-mediated selection on lung cancer evolution.
    Br J Cancer. 2021 Feb 24. pii: 10.1038/s41416-020-01232.
    PubMed     Abstract available

  42. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available

  43. WHITE MG, Schulte JJ, Xue L, Berger Y, et al
    Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy.
    Br J Cancer. 2021;124:564-566.
    PubMed     Abstract available

    January 2021
  44. SURAWEERA A, Duff A, Adams MN, Jekimovs C, et al
    Correction: Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer.
    Br J Cancer. 2021 Jan 26. pii: 10.1038/s41416-020-01242.

  45. BRAGA A, Elias KM, Horowitz NS, Berkowitz RS, et al
    When less is more: regarding the use of chest X-ray instead of computed tomography in screening for pulmonary metastasis in postmolar gestational trophoblastic neoplasia.
    Br J Cancer. 2021 Jan 8. pii: 10.1038/s41416-020-01209.
    PubMed     Abstract available

  46. SUGANO T, Masuda M, Takeshita F, Motoi N, et al
    Pharmacological blockage of transforming growth factor-beta signalling by a Traf2- and Nck-interacting kinase inhibitor, NCB-0846.
    Br J Cancer. 2021;124:228-236.
    PubMed     Abstract available

  47. BAE K, Kim JH, Jung H, Kong SY, et al
    A fusion of CD63-BCAR4 identified in lung adenocarcinoma promotes tumorigenicity and metastasis.
    Br J Cancer. 2021;124:290-298.
    PubMed     Abstract available

    December 2020
  48. BRANCHER S, Stoer NC, Weiderpass E, Damhuis RAM, et al
    Metformin use and lung cancer survival: a population-based study in Norway.
    Br J Cancer. 2020 Dec 2. pii: 10.1038/s41416-020-01186.
    PubMed     Abstract available

  49. LINDNER DJ, Wildey G, Parker Y, Dowlati A, et al
    CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer.
    Br J Cancer. 2020 Dec 1. pii: 10.1038/s41416-020-01192.
    PubMed     Abstract available

  50. STOREY CL, Hanna GG, Greystoke A
    Practical implications to contemplate when considering radical therapy for stage III non-small-cell lung cancer.
    Br J Cancer. 2020;123.
    PubMed     Abstract available

  51. PATEL P, Alrifai D, McDonald F, Forster M, et al
    Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi(R), AstraZeneca UK Limited).
    Br J Cancer. 2020;123.
    PubMed     Abstract available

    Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer.
    Br J Cancer. 2020;123.
    PubMed     Abstract available

  53. PAZ-ARES L
    Summary of 'The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms'.
    Br J Cancer. 2020;123.

  54. EVISON M
    The current treatment landscape in the UK for stage III NSCLC.
    Br J Cancer. 2020;123.
    PubMed     Abstract available

  55. PAZ-ARES L
    Foreword to 'The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms'.
    Br J Cancer. 2020;123.

  56. ZELLWEGER M, Gonzalez M
    Comment on: the myth of pulmonary metastasectomy.
    Br J Cancer. 2020;123:1833-1834.

  57. MACBETH F, Fallowfield DL
    Reply to 'Comment on "The myth of pulmonary metastasectomy'".
    Br J Cancer. 2020;123:1835-1836.

  58. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    PubMed     Abstract available

    November 2020
  59. KANG JH, Lee KH, Kim DW, Kim SW, et al
    A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer.
    Br J Cancer. 2020 Nov 16. pii: 10.1038/s41416-020-01055.
    PubMed     Abstract available

    October 2020
  60. YANG L, Zhou F, Zhuang Y, Liu Y, et al
    Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway.
    Br J Cancer. 2020 Oct 30. pii: 10.1038/s41416-020-01135.
    PubMed     Abstract available

  61. HANSEN MS, Licaj I, Braaten T, Lund E, et al
    The fraction of lung cancer attributable to smoking in the Norwegian Women and Cancer (NOWAC) Study.
    Br J Cancer. 2020 Oct 27. pii: 10.1038/s41416-020-01131.
    PubMed     Abstract available

  62. SIDDIQUI MA, Gollavilli PN, Ramesh V, Parma B, et al
    Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01095.
    PubMed     Abstract available

  63. CREELAN BC, Yeh TC, Kim SW, Nogami N, et al
    A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.
    Br J Cancer. 2020 Oct 5. pii: 10.1038/s41416-020-01099.
    PubMed     Abstract available

  64. SONG X, Gong J, Zhang X, Feng X, et al
    Plasma-based early screening and monitoring of EGFR mutations in NSCLC patients by a 3-color digital PCR assay.
    Br J Cancer. 2020;123:1437-1444.
    PubMed     Abstract available

    September 2020
  65. KIM TW, Hong DW, Park JW, Hong SH, et al
    CB11, a novel purine-based PPAR ligand, overcomes radio-resistance by regulating ATM signalling and EMT in human non-small-cell lung cancer cells.
    Br J Cancer. 2020 Sep 22. pii: 10.1038/s41416-020-01088.
    PubMed     Abstract available

  66. AMBROISE G, Yu TT, Zhang B, Kacal M, et al
    Systematic analysis reveals a functional role for STAMBPL1 in the epithelial-mesenchymal transition process across multiple carcinomas.
    Br J Cancer. 2020;123:1164-1177.
    PubMed     Abstract available

  67. TRAN CHAU V, Liu W, Gerbe de Thore M, Meziani L, et al
    Differential therapeutic effects of PARP and ATR inhibition combined with radiotherapy in the treatment of subcutaneous versus orthotopic lung tumour models.
    Br J Cancer. 2020;123:762-771.
    PubMed     Abstract available

    August 2020
  68. MACBETH F, Fallowfield L
    The myth of pulmonary metastasectomy.
    Br J Cancer. 2020;123:499-500.
    PubMed     Abstract available

  69. LI PETRI G, El Hassouni B, Sciarrillo R, Funel N, et al
    Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds.
    Br J Cancer. 2020;123:644-656.
    PubMed     Abstract available

  70. KOSMIDIS C, Sardeli C, Zarogoulidis P, Hohenforst-Schmidt W, et al
    Producing the appropriate model and drug for intratumoural ablation.
    Br J Cancer. 2020;123:335-336.
    PubMed     Abstract available

  71. NIEMEIJER AN, Sahba S, Smit EF, Lissenberg-Witte BI, et al
    Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy.
    Br J Cancer. 2020;123:392-402.
    PubMed     Abstract available

    July 2020
  72. GOMES F, Wong M, Battisti NML, Kordbacheh T, et al
    Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper.
    Br J Cancer. 2020 Jul 22. pii: 10.1038/s41416-020-0986.
    PubMed     Abstract available

  73. LUANPITPONG S, Rodboon N, Samart P, Vinayanuwattikun C, et al
    A novel TRPM7/O-GlcNAc axis mediates tumour cell motility and metastasis by stabilising c-Myc and caveolin-1 in lung carcinoma.
    Br J Cancer. 2020 Jul 20. pii: 10.1038/s41416-020-0991.
    PubMed     Abstract available

  74. CHEUNG VTF, Gupta T, Olsson-Brown A, Subramanian S, et al
    Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
    Br J Cancer. 2020;123:207-215.
    PubMed     Abstract available

    June 2020
  75. CICCOLINI J, Benzekry S, Barlesi F
    Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC.
    Br J Cancer. 2020 Jun 16. pii: 10.1038/s41416-020-0918.
    PubMed     Abstract available

  76. ALAM SK, Wang L, Ren Y, Hernandez CE, et al
    ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumour cell proliferation.
    Br J Cancer. 2020 Jun 5. pii: 10.1038/s41416-020-0923.
    PubMed     Abstract available

    May 2020
  77. ROSSI SM, Ryan BK, Kelly HM
    Evaluation of the activity of a chemo-ablative, thermoresponsive hydrogel in a murine xenograft model of lung cancer.
    Br J Cancer. 2020 May 27. pii: 10.1038/s41416-020-0904.
    PubMed     Abstract available

  78. HSIN IL, Chiu LY, Ou CC, Wu WJ, et al
    CD133 inhibition via autophagic degradation in pemetrexed-resistant lung cancer cells by GMI, a fungal immunomodulatory protein from Ganoderma microsporum.
    Br J Cancer. 2020 May 25. pii: 10.1038/s41416-020-0885.
    PubMed     Abstract available

  79. SURAWEERA A, Duff A, Adams MN, Jekimovs C, et al
    Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer.
    Br J Cancer. 2020 May 22. pii: 10.1038/s41416-020-0899.
    PubMed     Abstract available

  80. WELCH CA, Sweeting MJ, Lambert PC, Rutherford MJ, et al
    Impact on survival of modelling increased surgical resection rates in patients with non-small-cell lung cancer and cardiovascular comorbidities: a VICORI study.
    Br J Cancer. 2020 May 11. pii: 10.1038/s41416-020-0869.
    PubMed     Abstract available

  81. ZULATO E, Attili I, Pavan A, Nardo G, et al
    Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer.
    Br J Cancer. 2020 May 7. pii: 10.1038/s41416-020-0833.
    PubMed     Abstract available

    April 2020
  82. GELSOMINO F, Tiseo M, Barbieri F, Riccardi F, et al
    Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
    Br J Cancer. 2020 Apr 29. pii: 10.1038/s41416-020-0845.
    PubMed     Abstract available

  83. SAITO R, Miki Y, Abe T, Miyauchi E, et al
    11beta hydroxysteroid dehydrogenase 1: a new marker for predicting response to immune-checkpoint blockade therapy in non-small-cell lung carcinoma.
    Br J Cancer. 2020 Apr 27. pii: 10.1038/s41416-020-0837.
    PubMed     Abstract available

  84. JETTE NR, Radhamani S, Arthur G, Ye R, et al
    Correction: Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
    Br J Cancer. 2020 Apr 17. pii: 10.1038/s41416-020-0841.
    PubMed     Abstract available

  85. DAI W, Wang G, Chwa J, Oh ME, et al
    Mitochondrial division inhibitor (mdivi-1) decreases oxidative metabolism in cancer.
    Br J Cancer. 2020;122:1288-1297.
    PubMed     Abstract available

  86. VAN GEEL RMJM, van Brummelen EMJ, Eskens FALM, Huijberts SCFA, et al
    Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
    Br J Cancer. 2020;122:1166-1174.
    PubMed     Abstract available

    March 2020
  87. SAITO Y, Takahashi T, Obata Y, Nishida T, et al
    TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naive and imatinib-resistant gastrointestinal stromal tumours.
    Br J Cancer. 2020;122:658-667.
    PubMed     Abstract available

  88. ZHANG Q, Ganapathy S, Avraham H, Nishioka T, et al
    Nicotine exposure potentiates lung tumorigenesis by perturbing cellular surveillance.
    Br J Cancer. 2020;122:904-911.
    PubMed     Abstract available

    February 2020
  89. WATTENBERG MM, Asch D, Yu S, O'Dwyer PJ, et al
    Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
    Br J Cancer. 2020;122:333-339.
    PubMed     Abstract available

    January 2020
  90. URSO L, Cavallari I, Sharova E, Ciccarese F, et al
    Metabolic rewiring and redox alterations in malignant pleural mesothelioma.
    Br J Cancer. 2020;122:52-61.
    PubMed     Abstract available

    December 2019
  91. HOU P, Shi P, Jiang T, Yin H, et al
    DKC1 enhances angiogenesis by promoting HIF-1alpha transcription and facilitates metastasis in colorectal cancer.
    Br J Cancer. 2019 Dec 20. pii: 10.1038/s41416-019-0695.
    PubMed     Abstract available

    September 2019
  92. ZHAO J, Giri A, Zhu X, Shrubsole MJ, et al
    Calcium: magnesium intake ratio and colorectal carcinogenesis, results from the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2019 Sep 23. pii: 10.1038/s41416-019-0579.
    PubMed     Abstract available

    August 2019
  93. KORPHAISARN K, Morris V, Davis JS, Overman MJ, et al
    Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma.
    Br J Cancer. 2019 Aug 13. pii: 10.1038/s41416-019-0548.
    PubMed     Abstract available

    July 2019
  94. ELEZ E, Pericay C, Valladares-Ayerbes M, Bando I, et al
    A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients.
    Br J Cancer. 2019 Jul 31. pii: 10.1038/s41416-019-0537.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.